BiomX Inc.
PHGE-UN
New York Stock Exchange Arca0.04
USD
+0.00
- -
BiomX Inc.
PHGE-UN
(New York Stock Exchange Arca)
Recent
price
0.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BiomX Inc. operates as a clinical-stage microbiome company specializing in the development of customized natural and engineered phage therapies designed to target and eradicate harmful bacteria associated with chronic diseases. The company's core products include phage cocktail therapies such as BX004 for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa; BX211 in clinical development for diabetic foot osteomyelitis; BX001 targeting acne-prone skin; BX002 focused on bacterial strains linked to inflammatory bowel disease (IBD); and BX003 aimed at specific strains of Klebsiella pneumoniae. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions to address these targets to treat chronic diseases including cystic fibrosis, IBD, colorectal cancer, diabetic foot osteomyelitis, and skin conditions. Founded in 2017 and headquartered in Israel, BiomX has a global operational footprint with a focus on advancing its clinical pipeline through ongoing trials and strategic collaborations. The company completed a significant merger with Adaptive Phage Therapeutics and secured a $50 million financing round in 2024 to support its clinical and development activities. BiomX effectuated a 1-for-10 reverse stock split in August 2024 to improve marketability and liquidity of its common stock. In late 2024 and 2025, the company received milestone payments from the U.S. Defense Health Agency supporting its BX211 Phase 2 clinical trial and is advancing discussions on the regulatory pathway including FDA feedback on the potential use of real-world evidence for the approval of BX004. BiomX continues to expand its product portfolio and strategic alliances, aiming to commercialize novel phage therapies for unmet medical needs in chronic bacterial infections. Overall, BiomX operates within the biotechnology and biopharmaceutical industry segments focusing on microbiome and precision phage therapy technologies, targeting healthcare providers, clinical researchers, and patients worldwide. This description integrates the latest updates and reflects BiomX’s comprehensive product offerings, recent strategic changes including mergers, financing, trial advancements, and regulatory progress, providing a detailed view of the company’s operations and development focus.